Shareholder Alert: Robbins LLP Announces Geron Corporation (GERN) Sued for Misleading Shareholders

Shareholder rights law firm Robbins LLP announces that a purchaser of Geron Corporation (NASDAQ: GERN) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 19, 2018 and September 26, 2018. Geron is a biopharmaceutical company that focuses on the development of therapeutics for hematologic myeloid malignancies.

If you suffered a loss as a result of Geron's misconduct, click here.

Geron Corporation Inc. (GERN) Accused of Misleading Shareholders

According to the complaint, Geron was developing its drug imetelstat in partnership with Janssen Biotech Inc. This partnership was contingent upon the results of Geron's clinical drug study of imetelstat, called the IMbark trial. For IMbark to succeed, the trial's primary endpoints needed patients in the study to show at least 35% reduction on spleen volume and a minimum 50% reduction in Total Symptom Score ("TSS"). The actual results of the IMbark trial were disappointing and not even close to the results required for success, and IMbark was therefore determined a failure by a joint review committee consisting of Geron and Janssen employees. Despite these dismal results, in March 2018, Geron's CEO instead touted the median overall survival of IMbark patients, failing to disclose the disappointing results of its primary endpoints and causing Geron's stock to increase more than 28%. Then, on September 27, 2018, Geron finally admitted the failure of the IMbark trial and the consequent termination of its partnership with Janssen. On this news, the price of Geron's stock plummeted 62% to close at $2.31 per share and has yet to recover.

Geron Corporation Inc. (GERN) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on


Leo Kandinov
Robbins LLP
(619) 525-3990 or Toll Free (800) 350-6003